{
    "clinical_study": {
        "@rank": "65269", 
        "arm_group": {
            "arm_group_label": "13C-uracil and 99mTc sulfur colloid", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil."
        }, 
        "brief_summary": {
            "textblock": "This study is a multi-center, open-label comparison study and aimed to evaluate the\n      preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying\n      abnormal (accelerated or delayed) gastric emptying rates in subjects."
        }, 
        "brief_title": "Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dyspeptic Subjects", 
        "detailed_description": {
            "textblock": "Approximately equal numbers of subjects will be enrolled in each of the 3 groups (with\n      normal gastric emptying, with rapid (accelerated) gastric emptying, and with delayed gastric\n      emptying (gastroparesis)) to complete at least 10 subjects per group.\n\n      The subjects will first have their gastric emptying rates investigated by scintigraphy using\n      the Solid Test Meal containing 500 uCi 99mTc sulfur colloid at Visit 1.  Second, the\n      subjects will have their gastric emptying rates investigated by scintigraphy and 13C-uracil\n      GEBT simultaneously using the Semi solid Test Meal containing 500 uCi 99mTc sulfur colloid\n      and 100 mg of 13C-uracil, respectively, at Visit 2.  A comparison will be made between the\n      results obtained at Visits 1 and 2 along with a comparison of the data obtained during Visit\n      2 for evaluation of the 13C-uracil GEBT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index [range is 18.0 to 33.0 kg/m2\n\n          -  Subjects with any upper GI symptoms\n\n          -  Stable creatinine\n\n        Exclusion Criteria:\n\n          -  History of known peptic ulcers or stomach cancer.\n\n          -  History of stomach surgery or resection\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food or other substance, unless approved by the investigator\n\n          -  History of alcoholism or drug abuse\n\n          -  History or presence of clinically significant GI, cardiovascular, central nervous\n             system, hepatic, or renal disease; or other conditions\n\n          -  History of eating disorders\n\n          -  History or presence of an abnormal ECG, which, in the opinion of the investigator, is\n             clinically significant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677338", 
            "org_study_id": "URA-12-001"
        }, 
        "intervention": {
            "arm_group_label": "13C-uracil and 99mTc sulfur colloid", 
            "description": "Visit 2: Day 15+-4, perform the Breath Test and Scintigraphy with Semi solid Test Meal containing 100 mg of 13C-uracil and 500 uCi", 
            "intervention_name": "13C-uracil and 99mTc sulfur colloid", 
            "intervention_type": "Drug", 
            "other_name": "C13-URA and Technetium Tc 99m Sulfur Colloid Injection"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "drdever@compassresearch.com", 
                    "last_name": "Michael E Dever, M.D.", 
                    "phone": "407-426-9299"
                }, 
                "contact_backup": {
                    "last_name": "Judith A Chalykoff, M.D.", 
                    "phone": "(407) 426-9299"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research"
                }, 
                "investigator": {
                    "last_name": "Michael E Dever, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Brian.E.Lacy@hitchcock.org", 
                    "last_name": "Brian E Lacy, M.D.", 
                    "phone": "603-650-5261"
                }, 
                "contact_backup": {
                    "last_name": "Alan H Siegel, M.D.", 
                    "phone": "(603) 650-5261"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology"
                }, 
                "investigator": {
                    "last_name": "Brian E Lacy, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, Accelerated, and Delayed Gastric Emptying Time in Dyspeptic Subjects", 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Kimiyoshi Sudoh", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Expired 13CO2 concentrations are obtained from breath test.  The values will be calculated to Re(t)[B] semi-solid: remaining (%) of semi-solid test meal in stomach at t, t1/2[B] semi solid: half emptying time of semi-solid test meal , and tlag[B] semi-solid: lag time of semi-solid test meal.", 
            "measure": "Expired 13CO2 concentrations", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "PK parameters of 13C-uracil and its major metabolites, DHU and UPA, including AUCt, AUC\u221e, Cmax, tmax, \u03bbz, and t1/2,z, will be calculated based on plasma and urine concentration for 13C-uracil and its metabolites, and expired 13CO2-excretion, which calculated based on expired 13CO2 concentrations", 
            "measure": "Concentrations of 13C-uracil and its major metabolites in plasma and urine", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Covance", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}